Therapeutic potential of colchicine-binding site inhibitors in breast cancer brain metastasis
Cancer Letters · 2026
DOI: 10.1016/j.canlet.2026.218844 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2026. Verfasst von Kelli Adeleye und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA. Hauptthemen laut MEDLINE: Brain Neoplasms, Breast Neoplasms, Colchicine, Tubulin Modulators. Die Arbeit nennt 126 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health National Cancer Institute.
Abstract (Originalsprache)
Breast cancer brain metastasis (BCBM) represents one of the most aggressive and lethal complications of breast cancer, arising when malignant cells colonize the brain. Patients diagnosed with BCBM face a poor prognosis, with median survival times ranging from 2 to 25.3 months, and experience significantly reduced quality of life compared with those patients with extracranial metastases. Current therapeutic strategies, including surgical resection, whole-brain radiation therapy, and stereotactic radiosurgery, offer limited benefit and are rarely curative. Despite advances in breast cancer management, effective treatment for BCBM remains a major clinical challenge, primarily due to the restrictive nature of the blood-brain barrier (BBB), which hinders the delivery and accumulation of most chemotherapeutics within brain tissue. For example, paclitaxel, a widely used microtubule-targeting agent in breast cancer therapy, has limited efficacy against BCBM because it is a substrate of ATP-dependent efflux transporters, particularly P-glycoprotein, at the blood-brain barrier, with its physicochemical properties, such as high molecular weight, further restricting effective intracranial drug exposure. In contrast, emerging evidence suggests that colchicine-binding site inhibitors (CBSIs), a novel class of microtubule-targeting agents, possess the ability to penetrate the BBB, making them promising candidates for the treatment of BCBM. This review highlights recent advances in the development of CBSIs for BCBM and extends the discussion to their evaluation in other brain cancers, such as glioma. Furthermore, we examine strategies to enhance drug delivery across the BBB and to improve therapeutic selectivity toward cancer cells while sparing healthy brain tissue.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA.
- Department of Medicine and Tulane Cancer Center, School of Medicine, Tulane University, New Orleans, LA, USA.
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA. Electronic address: wli@uthsc.edu.
Förderung
- NCI NIH HHS
- National Institutes of Health National Cancer Institute
Zitieren
APA
Adeleye, K., Seagroves, T. N., & Li, W. (2026). Therapeutic potential of colchicine-binding site inhibitors in breast cancer brain metastasis. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218844
Vancouver
Adeleye K, Seagroves TN, Li W. Therapeutic potential of colchicine-binding site inhibitors in breast cancer brain metastasis. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218844
BibTeX
@article{Adeleye2026,
author = {Adeleye, Kelli and Seagroves, Tiffany N and Li, Wei},
title = {Therapeutic potential of colchicine-binding site inhibitors in breast cancer brain metastasis},
journal = {Cancer Letters},
year = {2026},
doi = {10.1016/j.canlet.2026.218844}
}
EUVIMED